US12378237B2ActiveUtilityPatentIndex 73
Compounds as GLP-1R agonists
Est. expirySep 27, 2041(~15.2 yrs left)· nominal 20-yr term from priority
A61P 3/10A61P 3/04A61P 9/00A61P 1/16A61K 31/4545C07D 417/14
73
PatentIndex Score
1
Cited by
241
References
20
Claims
Abstract
The present application provides compounds that may be used as a glucagon-like peptide-1 receptors (GLP-1R) agonist, or pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions containing such compounds, or pharmaceutically acceptable salts thereof. Methods of preparing these compounds and compositions, and methods of using these compounds and compositions to treat or prevent a disease or a condition mediated by GLP-1R, are also provided.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. A compound selected from
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein the compound is
4. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 , wherein the compound is
6. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 , wherein the compound is
8. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
9. The compound of claim 1 , wherein the compound is
10. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
11. The compound of claim 1 , wherein the compound is
12. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
13. The compound of claim 1 , wherein the compound is
14. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
15. The compound of claim 1 , wherein the compound is
16. The compound of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
17. The compound of claim 1 , wherein the compound is
18. The compound of claim 14 , wherein the compound is a meglumine salt of the compound.
19. A pharmaceutical composition comprising the compound of claim 18 and a pharmaceutically acceptable excipient.
20. A method of treating a disease mediated by glucagon-like peptide-1 receptor (GLP-1R) in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of the compound of claim 14 , or a pharmaceutically acceptable salt thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.